ArticleCardio-oncology (London, England)2026
Statin initiation among cancer survivors with asymptomatic coronary atherosclerosis.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer survivors are at higher risk of developing heart disease, but it is unclear whether they receive adequate preventive care. This study aimed to compare the statin initiation rates between cancer survivors and non-cancer controls.
methodsCancer survivors and similar statin-naïve controls were recruited from the community. Intermediate risk participants, based on their conventional cardiovascular risk factors, were referred for coronary artery calcium score (CACS). This result was relayed to participants’ primary care provider (PCP), who determined therapy. Multivariable logistic regression models were constructed to identify the associations between cancer history and statin initiation by PCP.
resultsThis study compared management of 97 cancer survivors (median age 67 [64–70] years, 84.5% female) and 109 non-cancer controls (median age 64 [60–67] years, 36.7% female). The median CACS for survivors and controls were 62 [16–124] and 144 [28–554] followed by the overall statin prescription rates of 54% and 69%, respectively. Multivariable logistic regression showed that cancer history was not associated with statin initiation by PCP after adjustment for CACS, age, sex and other cardiovascular risk factors.
conclusionStatin prescribing by primary care providers was generally aligned with guideline recommendations and did not differ substantially by cancer history. However, many individuals with any detectable coronary calcium (CACS > 0) remained untreated, despite this being a clear marker of elevated risk of atherosclerotic cardiovascular disease. These findings suggest that undertreatment may not be driven by clinical inertia alone, underscoring the need to explore alternative barriers to preventive care in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.